5 completed. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
Follow Postmenopausal: new trials by email Literature Review of Postmenopausal trials Research Report on Postmenopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women LAE102 SC, Placebo SC, LAE102 IV - Postmenopausal, Healthy Adult Female Participants | Phase 1 | Completed | Laekna Limited | 32 | 2025-04-22 | 2025-11-17 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive | Phase 1 | Completed | M.D. Anderson Cancer Center | 37 | 2014-07-17 | 2020-12-19 |
| AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations AZD1981 - Healthy, Postmenopausal | Phase 1 | Completed | AstraZeneca | 14 | 2009-06-01 | 2009-07-30 |
| Food Effects on the Relative Bioavailability of Different Dosages of Risedronate risedronate - Postmenopausal, Non-lactating | Phase 1 | Completed | Warner Chilcott | 94 | 2008-07-01 | 2011-10-12 |
| A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Romosozumab, Placebo - Postmenopausal, Osteopenia | Phase 1 | Completed | Amgen | 48 | 2007-11-14 | 2023-08-30 |
Bone Diseases, Metabolic (1) · Breast Neoplasms (1)
Bone Diseases (1) · Breast Diseases (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nutritional and Metabolic Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
AZD1981 (1) · Everolimus (1) · Letrozole (1) · Ogivri (1) · PF-05280014 (1) · Risedronic Acid (1) · Trastuzumab (1) · romosozumab (1) · trastuzumab biosimilar HLX02 (1)
Amgen (1) · AstraZeneca (1) · Laekna Limited (1) · M.D. Anderson Cancer Center (1) · Warner Chilcott (1)
United States (3) · Sweden (1)
Dr. Hugh Coleman, MD (1) · Elisabeth Eden (1) · Eva Pettersson (1) · Filip Janku (1)
P30CA016672 (1)